Should we treat smoldering myeloma?

Morie Gertz, MD, MACP, Mayo Clinic, Rochester, MN, shares his perspectives on whether patients with smoldering multiple myeloma (SMM) should be treated, commenting on these patients’ risk of progression to multiple myeloma. Dr Gertz cautions clinical practitioners against reflexively considering therapeutic intervention for patients with SMM if they are asymptomatic. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.